FDA approves new indication for apixaban

Candace Stuart | | Cardiovascular Business | Structural Heart Disease

The FDA has approved a supplemental New Drug Application for the anticoagulant apixaban for the prevention of deep vein thrombosis, which may lead to pulmonary embolism in patients who have undergone hip or knee replacement surgery.

Apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) was approved for this indication by the Europe Commission in 2011 based on the ADVANCE-2 and ADVANCE-3 trials. The FDA also based its decision on ADVANCE data, according to the companies.

The FDA previously approved apixaban, an oral direct Factor Xa inhibitor, in late 2012 to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Candace Stuart, Contributor

Related Content

CMS proposes Medicare coverage for transcatheter tricuspid valve replacement
Hydra TAVR valve gains key approval as global reach continues to grow
SAVR outperforms TAVR in patients with bicuspid aortic valves
Treating AFib patients with TAVR still linked to elevated risks
Heart surgeons detail world’s first robotic heart procedure of its kind
Years of progress have made TAVR more effective when treating concomitant mitral stenosis

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.